Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in chronically ischemic myocardium: A pilot study
Physiological Reports · 2023
DOI: 10.14814/phy2.15744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Reports, 2023. Verfasst von Sharif A Sabe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown Univ…. Hauptthemen laut MEDLINE: Myocardial Ischemia, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Dipeptidyl peptidase 4 inhibitors (DPP4i) may be cardioprotective based on several small animal and clinical studies, though randomized control trials have demonstrated limited benefit. Given these discrepant findings, the role of these agents in chronic myocardial disease, particularly in the absence of diabetes, is still poorly understood. The purpose of this study was to determine the effects of sitagliptin, a DPP4i, on myocardial perfusion and microvessel density in a clinically relevant large animal model of chronic myocardial ischemia. Normoglycemic Yorkshire swine underwent ameroid constrictor placement to the left circumflex artery to induce chronic myocardial ischemia. Two weeks later, pigs received either no drug (CON, n = 8) or 100 mg oral sitagliptin (SIT) daily ( n = 5). Treatment continued for 5 weeks, followed by hemodynamic measurements, euthanasia, and tissue harvest of ischemic myocardium. There were no significant differences in myocardial function between CON and SIT as measured by stroke work ( p > 0.5), cardiac output ( p = 0.22), and end‐systolic elastance ( p = 0.17). SIT was associated with increased absolute blood flow at rest (17% increase, IQR 12–62, p = 0.045) and during pacing (89% increase, IQR 83–105, p = 0.002). SIT was also associated with improved arteriolar density ( p = 0.045) compared with CON, without changes in capillary density ( p = 0.72). SIT was associated with increased expression of pro‐arteriogenic markers MCP‐1 ( p = 0.003), TGFß ( p = 0.03), FGFR1 ( p = 0.002), and ICAM‐1 ( p = 0.03), with a trend toward an increase in the ratio of phosphorylated/active PLCγ1 to total PLCγ1 ( p = 0.11) compared with CON. In conclusion, in chronically ischemic myocardium, sitagliptin improves myocardial perfusion and arteriolar collateralization via the activation of pro‐arteriogenic signaling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island, USA.
ORCID-Profile: Sharif A Sabe, Dwight Douglas Harris, Mark Broadwin, Cynthia M Xu, M Ruhul Abid, Frank W Sellke
Förderung
- NHLBI NIH HHS
Zitieren
APA
Sabe, S. A., Harris, D. D., Broadwin, M., Sabra, M., Xu, C. M., Banerjee, D., Abid, M. R., & Sellke, F. W. (2023). Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in chronically ischemic myocardium: A pilot study. Physiological Reports. https://doi.org/10.14814/phy2.15744
Vancouver
Sabe SA, Harris DD, Broadwin M, Sabra M, Xu CM, Banerjee D, et al. Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in chronically ischemic myocardium: A pilot study. Physiological Reports. 2023. doi:10.14814/phy2.15744
BibTeX
@article{Sabe2023,
author = {Sabe, Sharif A and Harris, Dwight Douglas and Broadwin, Mark and Sabra, Mohamed and Xu, Cynthia M and Banerjee, Debolina and Abid, M Ruhul and Sellke, Frank W},
title = {Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in chronically ischemic myocardium: A pilot study},
journal = {Physiological Reports},
year = {2023},
doi = {10.14814/phy2.15744}
}
EUVIMED